Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2012 1
2013 1
2014 1
2015 1
2016 1
2017 1
2020 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Experience with fingolimod in clinical practice.
Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D. Hersh CM, et al. Among authors: hara cleaver c. Int J Neurosci. 2015;125(9):678-85. doi: 10.3109/00207454.2014.969839. Epub 2014 Oct 29. Int J Neurosci. 2015. PMID: 25271798 Free PMC article.
Technology-enabled assessments to enhance multiple sclerosis clinical care and research.
Macaron G, Moss BP, Li H, Baldassari LE, Rao SM, Schindler D, Alberts JL, Weber M, Ayers M, Bethoux F, Boissy A, Chizmadia D, Conway DS, Fink C, Fox RJ, Gales S, Green B, Hara-Cleaver C, Jordan N, Mahajan KR, McGinley MP, Miller DM, Namey M, Rae-Grant A, Rensel M, Young H, Willis MA, Ontaneda D, Cohen JA, Bermel RA. Macaron G, et al. Among authors: hara cleaver c. Neurol Clin Pract. 2020 Jun;10(3):222-231. doi: 10.1212/CPJ.0000000000000710. Neurol Clin Pract. 2020. PMID: 32642324 Free PMC article.
Early tolerability and safety of fingolimod in clinical practice.
Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Ontaneda D, et al. Among authors: hara cleaver c. J Neurol Sci. 2012 Dec 15;323(1-2):167-72. doi: 10.1016/j.jns.2012.09.009. Epub 2012 Oct 3. J Neurol Sci. 2012. PMID: 23040960 Free PMC article.
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators. Cohen JA, et al. Among authors: hara cleaver c. Neurology. 2009 Feb 10;72(6):535-41. doi: 10.1212/01.wnl.0000341934.12142.74. Neurology. 2009. PMID: 19204263 Clinical Trial.
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.
Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D. Hersh CM, et al. Among authors: hara cleaver c. Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep. Mult Scler J Exp Transl Clin. 2017. PMID: 28890796 Free PMC article.
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H; ACT Investigators. Cohen JA, et al. Among authors: hara cleaver c. Mult Scler. 2008 Apr;14(3):370-82. doi: 10.1177/1352458507083189. Epub 2008 Jan 21. Mult Scler. 2008. PMID: 18208877 Clinical Trial.